PDSB — PDS Biotechnology Income Statement
0.000.00%
Last trade - 00:00
- $110.46m
- $77.10m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.7 | 14.9 | 21.4 | 41.7 | 43 |
Operating Profit | -7.7 | -14.9 | -21.4 | -41.7 | -43 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.38 | -14.8 | -21.4 | -42.1 | -44.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7 | -14.8 | -16.9 | -40.9 | -42.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -7 | -14.8 | -16.9 | -40.9 | -42.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7 | -14.8 | -16.9 | -40.9 | -42.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.41 | -0.857 | -0.661 | -1.43 | -1.39 |